Helex
Genomic medicines for kidney diseases with high unmet need
Helex is active in the biopharma space based in Greater New York Area, East Coast, Northeastern US, founded in 2016.
Profile
Helex is taking the promise of non-viral targeted delivery and genome editing to the kidney, developing first-in-class genetic medicines for renal indications. Helex combines its proprietary kidney tropic lipid nanoparticle delivery system with the Epic-Cure™ 3D genome-based drug designer platform to create a robust renal franchise of precise and scalable therapeutics. Our lead asset is a mutation-agnostic, potential one-and-done therapy for Autosomal Dominant Polycystic Kidney Disease that impacts over 4 million people worldwide.
Helex is positioned in biopharma, a segment that rewards a clear, focused offering.
The company is recorded as being based in Greater New York Area, East Coast, Northeastern US.
Its current recorded stage is Convertible_Note.
Its team size is recorded as 2-10 employees.
Public records show total funding of about $1.1M.
| Sector | Biopharma |
|---|---|
| Headquarters | Greater New York Area, East Coast, Northeastern US |
| Country | United States |
| Founded | 2016 |
| Employees | 2-10 |
| Stage | convertible_note |
| Total funding | $1,125,000 |
Website: www.helex.bio
Create a free account